Clearmind Medicine Inc.
CMND
Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to address underserved health issues. Its primary efforts center on treatments for alcohol use disorder, including the lead candidate CMND-100, which is in an FDA-approved Phase I/IIa clinical trial, and MEAI, a non-hallucinogenic neuroplastogen targeted at obesity, metabolic disorders, compulsive eating, binge drinking, eating disorders, anxiety, depression, and post-traumatic stress disorder. The company also explores intranasal formulations and collaborations to enhance drug delivery for addiction-related and central nervous system conditions. Clearmind Medicine Inc. maintains an extensive intellectual property portfolio comprising 15 patent families with granted and pending patents across multiple jurisdictions. Founded in 2017 and headquartered in Vancouver, Canada, it operates as a key player in the emerging field of psychedelic medicines for mental health and behavioral disorders.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$8M
▲ +26.6% YoY
Op. Margin
–
ROIC
-146.02%
▲ +90.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$6M
▲ +2.6% YoY
Op. Cash Flow (TTM)
-$5M
▲ +31.3% YoY
Net Debt
-$4M
Net Cash Position
Cash & Equiv.
$6M
Continue Research
Peers
Biotechnology · Pick stocks to compare with CMND
Clearmind Medicine (CMND) in three numbers
Questions about Clearmind Medicine
Is Clearmind Medicine a high-quality business?
Clearmind Medicine scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$4M, and its weakest is return on capital at -146.0%. The Quality tab shows every check against its target.
Does Clearmind Medicine (CMND) pay a dividend?
No. Clearmind Medicine (CMND) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CMND
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.